Clinical trial

ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

NCT00477529

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-04-01

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2007-04-01Date precision: day

Registry last updated2019-11-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Hormone Refractory Prostate Cancerunresolved

Interventions

ABI-008DRUG

Sponsors & collaborators

Celgenelead sponsor

Mapped research locations

HoustonTexas, United States1 St LouisMissouri, United States1 OmahaNebraska, United States1 Ann ArborMichigan, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00477529 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.